ROS1 and non-small cell lung carcinoma: Furthermore, the sensitivity analysis highlighted that the cost of taletrectinib was the primary driver of the ICER's unfavorable results.<h4>Conclusion</h4>Based on current pricing, none of the taletrectinib-containing treatment strategies were found to be cost-effective for patients with ROS1-positive NSCLC compared to chemotherapy alone, as their ICERs exceeded the established WTP threshold.